Диссертация (1154347), страница 34
Текст из файла (страница 34)
[et al.] // BMC Med. Genet. — 2014. — Vol. 15. — P. 3.245. Retrospective review of serum and urinary lithogenic risk factors in patientswith osteoporosis and osteopenia / Arrabal-Polo M.A., Girón-Prieto M.S., Cano-GarcíaMdel C. [et al.] // Urology. — 2015. — Vol. 85. — P. 782-785.246. Richman, K. The growing prevalence of kidney stones and opportunities forprevention / Richman K., O'Bell J., Pareek G. // R.
I. Med. J. — 2014. — Vol. 97. — P.31-34.247. Risk factors associated with renal lithiasis during uricosuric treatment ofhyperuricemia in patients with gout / Perez-Ruiz F., Hernandez-Baldizon S., HerreroBeites A.M., Gonzalez-Gay M.A. // Arthritis Care Res. (Hoboken). — 2010. —Vol. 2. — P. 299-305.248. Rogozin, D.S. Screening of primary hyperparathyroidism in patients withurolithiasis / Rogozin D.S., Sergiyko S.V., Rogozina A.A. // Vestn. Khir.
Im. I. I. Grek.— 2015. — Vol. 174. — P. 56-58.249. Romero, V. Kidney Stones: A Global Picture of Prevalence, Incidence, andAssociated Risk Factors / Romero V., Akpinar H., Assimos D.G. // Rev. Urol. — 2010.— Vol. 12. — N 2 - 3. — P. 86-96.250. Roudakova, K. The evolving epidemiology of stone disease / Roudakova K.,Monga M. // Indian J.
Urol. — 2014. — Vol. 30. — P. 44-48.251. Sadaf, H. Role of gut microbiota against calcium oxalate / Sadaf H., Raza S.I.,Hassan S.W. // Microb. Pathog. — 2017. — Vol. 109. — P. 287-291.252. Sas, D.J. An update on the changing epidemiology and metabolic risk factors219in pediatric kidney stone disease / Sas D.J.
// Clin. J. Am. Soc. Nephrol. — 2011. — Vol.6. — P. 2062–2068.253. Sawicka-Kamińska, A. The long-term results of the treatment of renalhypercalciuria - a report of two cases / Sawicka-Kamińska A, Szymanik-Grzelak H,Szymanik-Grzelak M. // Pol. Merkur. Lekarski. — 2017. — Vol. 23. — №42. — Р. 260263.254.
Schwaderer, A.L. The association between bacteria and urinary stones /Schwaderer A.L., Wolfe A.J. // Ann. Transl. Med. — 2017. — Vol. 5. — P. 32.255. Seitz, C. Epidemiological gender-specific aspects in urolithiasis / Seitz C.,Fajkovic H. // World J.
Urol. — 2013. — Vol.31. — P. 1087-1092.256. Sodium Thiosulfate: An Emerging Treatment for Calciphylaxis in DialysisPatients / Yu Z., Gu L., Pang H. [et al.] // Case Rep. Nephrol. Dial. — 2015. — №5. —Р. 77–82.257. Sorensen, M.D. Calcium intake and urinary stone disease / Sorensen M.D. //Transl. Androl. Urol. — 2014. — Vol. 3. — №3. — P. 235–240.258.
Stone Composition Among First-Time Symptomatic Kidney Stone Formersin the Community / Singh P., Enders F.T., Vaughan L.E. [et al.] // Mayo. Clin. Proc. —2015. — Vol. 90. — №10. — P. 1356-1365.259. Strope, S.A. Changes in gender distribution of urinary stone disease /Strope S.A., Wolf J.S., Hollenbeck B.K. // Urology. — 2010. — Vol. 75. — P. 543–546.260. Tailly, G.G. Extracorporeal shock wave lithotripsy today / Tailly G.G. //Indian J. Urol. — 2013. — Vol. 29. — № 3. — P.
200–207.261. Temporal Changes in Kidney Stone Composition and in Risk FactorsPredisposing to Stone Formation / Xu L.H.R., Adams-Huet B., Poindexter J.R. [et al.] //J. Urol. — 2017. — Vol.197 — № 6. — Р. 1465-1471.262. Thanassi, David G. Surface Organelles Assembled by Secretion Systems ofGram-Negative Bacteria: Diversity in Structure and Function / David G. Thanassi, JamesB.
Bliska, Peter J. Christie. // FEMS Microbiol. Rev. — 2012. — Vol.36. — P. 1046–1082.263. The association of nephrolithiasis with metabolic syndrome and its220components: a cross-sectional analysis / Liu Y.-T., Yang P.-Y., Yang Y.-W. [et al.] //Ther. Clin. Risk. Manag. — 2017. — Vol. 13. — P. 41–48.264. The most important metabolic risk factors in recurrent urinary stone formers/ Parvin M., Shakhssalim N., Basiri A. [et al.] // Urol. J. — 2011. — Vol.
8. — P. 99-106.265. Thiazide Diuretic Prophylaxis for Kidney Stones and the Risk of DiabetesMellitus / Singh P., Knoedler J.J., Krambeck A.E. [et al.] // J. Urol. — 2014. —Vol.192. — P. 1700–1704.266. Three pathways for human kidney stone formation. Urol Res. Authormanuscript; available in PMC 2011 September 7 / Coe F.L., Evan A.P., Worcester E.M.,Lingeman J.E. // Urol. Res. — 2010. — Vol. 38 (3). — P. 147–160.267. Tracy, C.R. Update on the medical management of stone disease / Tracy C.R.,Pearle M.S. // Curr.
Opin. Urol. — 2009. — Vol. 19. — № 2. — P. 200-204.268. Trends in urological stone disease / Turney B.W., Reynard J.M., Noble J.G.,Keoghane S.R. // BJU Int. — 2012. — Vol. 109. — P. 1082–1087.269. Trinchieri, A. Prevalence of renal uric acid stones in the adult / Trinchieri A.,Montanari E. // Urolithiasis. — 2017. — Vol. 45. — № 6. — P. 553-562.270.
Urinary lithogenic risk profile in recurrent stone formers with hyperoxaluria:a randomized controlled trial comparing DASH (Dietary Approaches to StopHypertension)-style and low-oxalate diets / Noori N., Honarkar E., Goldfarb D.S.[et al.] // Am. J. Kidney Dis. — 2014. — Vol. 63.
— №3. — Р. 456-463.271. Urine risk factors in children with calcium kidney stones and their siblings /Bergsland K.J., Coe F.L., White M.D. [et al.] // Kidney Int. — 2012. — Vol. 81. —P. 1140-1148.272. Urolithiasis and crohn's disease / Gaspar da Silva S.R., Mendonça T.,Oliveira P. [et al.] // Urol. Ann. — 2016. — Vol. 8. — P. 297–304.273.
Urolithiasis and urinary tract infection among patients with inflammatorybowel disease: a review of US emergency department visits between 2006 and 2009 /Varda B.K., McNabb-Baltar J., Sood A. [et al.] // Urology. — 2015. — Vol. 85. —№4. — P. 764-770.274. Urolithiasis in Italy: an epidemiological study. Prezioso D., Illiano E.,221Piccinocchi G. [et al.] // Arch.
Ital. Urol. Androl. — 2014. — Vol. 86. – P. 99-102.275. Urolithiasis—an Interdisciplinary Diagnostic, Therapeutic and SecondaryPreventive Challenge. Fisang Ch., Anding R., Müller S.C. [et al.] // Dtsch. Arztebl. Int. —2015. — Vol. 112. — P. 83–91.276. Urologic Diseases in America Project.
Prevalence of kidney stones in theUnited States / Scales C.D., Smith A.C., Hanley J.M., Saigal C.S. // Eur. Urol. — 2012. —Vol. 62. — P. 160–165.277. Vigen, R. Thiazides diuretics in the treatment of nephrolithiasis: are we usingthem in an evidence-based fashion? / Vigen R., Weideman R.A., Reilly R.F. // Int Urol.Nephrol. — 2011. — Vol. 43.
— № 3. — P. 813–819.278. Vitamin B6 in Primary Hyperoxaluria I: First Prospective Trial after 40 Yearsof Practice / Hoyer-Kuhn H., Kohbrok S., Volland R. [et al.] // Clin. J. Am. Soc.Nephrol. — 2014. — Vol. 9. — P. 468–477.279. Vitamin D Intake and the Risk of Incident Kidney Stones / Ferraro P.M.,Taylor E.N., Gambaro G., Curhan G.C. // J.
Urol. — 2017. — Vol. 197. — P. 405-410.280. Wood, K.D. Medical expulsive therapy / Wood K.D., Gorbachinsky I.,Gutierrez J. // Indian J. Urol. — 2014. — Vol. 30. — № 1. — 60–64.281. X-ray microdiffraction and urine: a new analysis method of crystalluria /Baggio B., Giannossi M.L., Medici L. [et al.]. // J. Xray Sci.
Technol. — 2012. —Vol. 20. — P. 489-98.282. Zhang, P. Effects of vitamin D receptor polymorphisms on urolithiasis risk: ameta-analysis / Zhang P., Nie W., Jiang H. // BMC Med. Genet. — 2013. — №14. — Р.104..
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
